Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study

Vincent Chouraki, Alexa Beiser, Linda Younkin, Sarah Rosner Preis, Galit Weinstein, Oskar Hansson, Ingmar Skoog, Jean Charles Lambert, Rhoda Au, Lenore Launer, Philip A. Wolf, Steven G Younkin, Sudha Seshadri

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community-based studies to date. Methods A total of 2189 dementia-free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ1-42 and Aβ1-40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD. Results Increased plasma Aβ1-42 levels were associated with lower risk of dementia (Aβ1-42: hazard ratio [HR] = 0.80 [0.71†0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.86 [0.76†0.98], P =.027) and AD (Aβ1-42: HR = 0.79 [0.69†0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.83 [0.72†0.96], P =.012). Conclusion Our results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia. They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia.

Original languageEnglish (US)
Pages (from-to)249-257.e1
JournalAlzheimer's and Dementia
Volume11
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Amyloid
Alzheimer Disease
Dementia
Biomarkers
Costs and Cost Analysis
Peptides

Keywords

  • Alzheimer's disease
  • Aβ peptides
  • Epidemiology
  • Framingham
  • Heart
  • Incident
  • Incident dementia
  • Meta-analysis
  • Plasma biomarker
  • Study

ASJC Scopus subject areas

  • Clinical Neurology
  • Developmental Neuroscience
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Epidemiology
  • Health Policy

Cite this

Chouraki, V., Beiser, A., Younkin, L., Preis, S. R., Weinstein, G., Hansson, O., ... Seshadri, S. (2015). Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study. Alzheimer's and Dementia, 11(3), 249-257.e1. https://doi.org/10.1016/j.jalz.2014.07.001

Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study. / Chouraki, Vincent; Beiser, Alexa; Younkin, Linda; Preis, Sarah Rosner; Weinstein, Galit; Hansson, Oskar; Skoog, Ingmar; Lambert, Jean Charles; Au, Rhoda; Launer, Lenore; Wolf, Philip A.; Younkin, Steven G; Seshadri, Sudha.

In: Alzheimer's and Dementia, Vol. 11, No. 3, 01.03.2015, p. 249-257.e1.

Research output: Contribution to journalArticle

Chouraki, V, Beiser, A, Younkin, L, Preis, SR, Weinstein, G, Hansson, O, Skoog, I, Lambert, JC, Au, R, Launer, L, Wolf, PA, Younkin, SG & Seshadri, S 2015, 'Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study', Alzheimer's and Dementia, vol. 11, no. 3, pp. 249-257.e1. https://doi.org/10.1016/j.jalz.2014.07.001
Chouraki V, Beiser A, Younkin L, Preis SR, Weinstein G, Hansson O et al. Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study. Alzheimer's and Dementia. 2015 Mar 1;11(3):249-257.e1. https://doi.org/10.1016/j.jalz.2014.07.001
Chouraki, Vincent ; Beiser, Alexa ; Younkin, Linda ; Preis, Sarah Rosner ; Weinstein, Galit ; Hansson, Oskar ; Skoog, Ingmar ; Lambert, Jean Charles ; Au, Rhoda ; Launer, Lenore ; Wolf, Philip A. ; Younkin, Steven G ; Seshadri, Sudha. / Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study. In: Alzheimer's and Dementia. 2015 ; Vol. 11, No. 3. pp. 249-257.e1.
@article{7554659ce835481bb09a67c2e7302f8c,
title = "Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study",
abstract = "Background Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community-based studies to date. Methods A total of 2189 dementia-free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56{\%} women) had plasma Aβ1-42 and Aβ1-40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD. Results Increased plasma Aβ1-42 levels were associated with lower risk of dementia (Aβ1-42: hazard ratio [HR] = 0.80 [0.71{\^a}€ 0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.86 [0.76{\^a}€ 0.98], P =.027) and AD (Aβ1-42: HR = 0.79 [0.69{\^a}€ 0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.83 [0.72{\^a}€ 0.96], P =.012). Conclusion Our results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia. They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia.",
keywords = "Alzheimer's disease, Aβ peptides, Epidemiology, Framingham, Heart, Incident, Incident dementia, Meta-analysis, Plasma biomarker, Study",
author = "Vincent Chouraki and Alexa Beiser and Linda Younkin and Preis, {Sarah Rosner} and Galit Weinstein and Oskar Hansson and Ingmar Skoog and Lambert, {Jean Charles} and Rhoda Au and Lenore Launer and Wolf, {Philip A.} and Younkin, {Steven G} and Sudha Seshadri",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.jalz.2014.07.001",
language = "English (US)",
volume = "11",
pages = "249--257.e1",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study

AU - Chouraki, Vincent

AU - Beiser, Alexa

AU - Younkin, Linda

AU - Preis, Sarah Rosner

AU - Weinstein, Galit

AU - Hansson, Oskar

AU - Skoog, Ingmar

AU - Lambert, Jean Charles

AU - Au, Rhoda

AU - Launer, Lenore

AU - Wolf, Philip A.

AU - Younkin, Steven G

AU - Seshadri, Sudha

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community-based studies to date. Methods A total of 2189 dementia-free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ1-42 and Aβ1-40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD. Results Increased plasma Aβ1-42 levels were associated with lower risk of dementia (Aβ1-42: hazard ratio [HR] = 0.80 [0.71†0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.86 [0.76†0.98], P =.027) and AD (Aβ1-42: HR = 0.79 [0.69†0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.83 [0.72†0.96], P =.012). Conclusion Our results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia. They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia.

AB - Background Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community-based studies to date. Methods A total of 2189 dementia-free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ1-42 and Aβ1-40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD. Results Increased plasma Aβ1-42 levels were associated with lower risk of dementia (Aβ1-42: hazard ratio [HR] = 0.80 [0.71†0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.86 [0.76†0.98], P =.027) and AD (Aβ1-42: HR = 0.79 [0.69†0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.83 [0.72†0.96], P =.012). Conclusion Our results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia. They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia.

KW - Alzheimer's disease

KW - Aβ peptides

KW - Epidemiology

KW - Framingham

KW - Heart

KW - Incident

KW - Incident dementia

KW - Meta-analysis

KW - Plasma biomarker

KW - Study

UR - http://www.scopus.com/inward/record.url?scp=84925961850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925961850&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2014.07.001

DO - 10.1016/j.jalz.2014.07.001

M3 - Article

VL - 11

SP - 249-257.e1

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 3

ER -